Organic compounds -- part of the class 532-570 series – Organic compounds – Sulfur containing
Reexamination Certificate
2000-08-15
2003-04-08
Pryor, Alten N (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Sulfur containing
Reexamination Certificate
active
06545184
ABSTRACT:
BACKGROUND OF THE INVENTION
The ubiquinones, also commonly called coenzyme Q
n
(n=1-12), constitute essential cellular components of many life forms. In humans, CoQ
10
is the predominant member of this class of polyprenoidal natural products and is well-known to function primarily as a redox carrier in the respiratory chain (Lenaz,
Coenzyme Q. Biochemistry, Bioenergetics, and Clinical Applications of Ubiquinone
, Wiley-Interscience: New York (1985); Trumpower,
Function of Ubiquinones in Energy Conserving Systems
, Academic Press, New York (1982); Thomson, R. H.,
Naturally Occurring Quinones
, 3rd ed., Academic Press, New York (1987); Bliznakov et al.,
The Miracle Nutrient Coenzyme Q
10
, Bantom Books, New York (1987)).
Coenzyme Q plays an essential role in the orchestration of electron-transfer processes necessary for respiration. Almost all vertebrates rely on one or more forms of this series of compounds which are found in the mitrochondria of every cell (i.e., they are ubiquitous, hence the alternative name “ubiquinones”). Although usually occurring with up to 12 prenoidal units attached to a p-quinone headgroup, CoQ
10
is the compound used by humans as a redox carrier. Oftentimes unappreciated is the fact that when less than normal levels are present, the body must construct its CoQ
10
from lower forms obtained through the diet, and that at some point in everyone's life span the efficiency of that machinery begins to drop. (Blizakov et al., supra) The consequences of this in vivo deterioration can be substantial; levels of CoQ
10
have been correlated with increased sensitivity to infection (i.e., a weakening of the immune system), strength of heart muscle, and metabolic rates tied to energy levels and vigor. In some countries (e.g., Japan), CoQ
10
is treated as a “drug”, prescribed especially for those having suffered from heart disease, and is among the leading pharmaceuticals sold. In the United States, however, it is considered a dietary supplement, sold typically in health food stores or through mail order houses at reasonable prices. It is indeed fortunate that quantities of CoQ
10
are available via well-established fermentation and extraction processes (e.g., Sasikala et al.,
Adv. Appl. Microbiol
., 41:173 (1995); U.S. Pat. Nos. 4,447,362; 3,313,831; and 3,313,826) an apparently more cost-efficient route relative to total synthesis. However, for producing lower forms of CoQ, such processes are either far less efficient or are unknown. Thus, the costs of these materials for research purposes are astonishingly high, e.g., CoQ
6
is ~$22,000/g, and CoQ
9
is over $40,000/g. (Sigma-Aldrich Catalog, Sigma-Aldrich: St. Louis, pp. 306-307 (1998)).
Several approaches to synthesizing the ubiquinones have been developed over the past 3-4 decades, attesting to the importance of these compounds. Recent contributions have invoked such varied approaches as Lewis acid-induced prenoidal stannane additions to quinones, (Naruta,
J. Org. Chem
., 45:4097 (1980)) reiterative Pd(0)-catalyzed couplings of doubly activated prenoidal chains with allylic carbonates bearing the required aromatic nucleus in protected form (Eren et al.,
J. Am. Chem. Soc
., 110:4356 (1988) and references therein), and a Diels-Alder, retro Diels-Alder route to arrive at the quinone oxidation state directly (Van Lient et al.,
Rec. Trav. Chim. Pays-Bays
113:153 (1994); and Rüittiman et al.,
Helv. Chim. Acta
, 73:790 (1990)). Nonetheless, all are lengthy, linear rather than convergent, and/or inefficient. Moreover, problems in controlling double bond stereochemistry using, e.g., a copper(I)-catalyzed allylic Grignard-allylic halide coupling can lead to complicated mixtures of geometrical isomers that are difficult to separate given the hydrocarbon nature of the side chains (Yanagisawa, et al.,
Synthesis
, 1130 (1991)).
For the reasons set forth above, a convergent method for the synthesis of the ubiquinones and their analogues which originates with a simple benzenoid precursor and procedes with retention of the double bond stereochemistry would represent a significant advance in the synthesis of ubiquinones and their analogues. The present invention provides such a method and ubiquinone precursors of use in the method.
SUMMARY OF THE INVENTION
The present invention provides an efficient and inexpensive method for preparing ubiquinones and structural analogues of these essential molecules. Also provided are new compounds that are structurally simple and provide a convenient, efficient and inexpensive entry into the method of the invention.
Thus, in a first aspect, the present invention provides a compound according to Formula I:
In Formula I, R
1
, R
2
and R
3
are independently selected C
1
-C
6
alkyl groups, preferably methyl groups. R
4
represents H or a protecting group. R
5
is selected from branched, unsaturated alkyl, —C(O)H, and —CH
2
Y, in which Y is OR
6
, SR
6
, NR
6
R
7
, or a leaving group. R
6
and R
7
are independently selected from H and branched, unsaturated alkyl.
In a second aspect, the present invention provides a method for preparing a compound according to Formula IV:
In Formula IV, each of R
1
, R
2
and R
3
is an independently selected C
1
-C
6
alkyl group and the subscript n represents an integer from 0 to 13.
The method of the invention comprises, contacting a compound according to Formula V:
with a compound according to Formula VI:
In Formula V, R
1
, R
2
, R
3
are as discussed above. Y is a leaving group and R
4
is a protecting group. In Formula VI, L is an organometallic ligand; M is a metal; p is an integer from 1 to 5; and n is an integer from 0 to 13. Each of the organometallic ligands, L, can be the same or different.
The compounds according to Formulae V and VI are contacted in the presence of a catalyst that is effective at catalyzing coupling between a benzylic carbon atom, such as that in Formula V and an organometallic species according to Formula VI. The coupling of the compounds of Formulae V and VI, forms a compound according to Formula VII:
The protecting group R
4
is preferably removed from the compound according to Formula VII to produce a compound according to Formula VIII:
The phenol is oxidized to the quinone of Formula IV, by contacting the compound according to Formula VIII with an oxidant.
Other objects and advantages of the invention will be apparent to those of skill in the art from the detailed description that follows.
REFERENCES:
patent: 3313826 (1967-04-01), Gale
patent: 3313831 (1967-04-01), Gale
patent: 4447362 (1984-05-01), Watanabe et al.
patent: 49080031 (1974-08-01), None
Eren, et al., “Total synthesis of linear polyrenoids. 31Synthesis of ubiquinones via palladium-catalyzed oligomerization of monoterpene monomers,”J. Am. Chem. Soc., 110:4356-4362 (1988).
Hooz, et al., “Progargylation of Alkyl Halides: Synthesis of (E)-6,10-Dimethyl-5,9-Undecadien-1-YNE and (E)-7,11-Dimethyl-6,10-Dodecadien-2-YN-1-OL,”Org. Syn., 69:120-129 (1990).
Lipshutz, et al., “A convergent approach to coenzyme Q,”J. Am. Chem. Soc., 121:11664-11673 (1999).
Lipshutz, et al., “Nickel on charcoal (“Ni/C”): An expedient and inexpensive heretogeneous catalyst for cross-couplings, between aryl chlorides and organometallics. I functionalized organozinc reagents”J. Am. Chem. Soc., 121:5819-5820 (1999).
Lipshutz, et al., “A novel route to coenzyme Qn”J. Am. Chem. Soc., 118:5512-5313 (1996).
Lipshutz, et al., “Biaryls via Suzuki cross-couplings catalyzed by nickel on charcoal,”Tetrahedron, 56:2139-2144 (2000).
Lipshutz, et al., “Kumada couplings catalyzed by nickel on charcoal (Ni/C),”Inorganica Chimica Acta, 296:164-169 (1999).
Naruta, “Regio- and steroselective synthesis of coenzymes Qn(n=2-10), Vitamin K, and related polyprenylquinones,”J. Am. Chem., 45:4097-4104 (1980).
Rüttiman, et al., “80. Ein neuer syntheischer Zugang zu Ubichinonen,”Helvetica Chimica Acta, 73:790-796 (1990).
Sasikala, et al., “Biotechnological potentials of anoxygenic phototrophic bacteria. I. Production of single-cell proteins, vitamins, ubiquinones, hormones, and e
Pryor Alten N
The Regents of the University of California
LandOfFree
Practical, cost-effective synthesis of COQ10 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Practical, cost-effective synthesis of COQ10, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Practical, cost-effective synthesis of COQ10 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3083689